Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

by · The Markets Daily

HC Wainwright reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

GANX has been the topic of several other research reports. Oppenheimer reiterated an outperform rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Wednesday, August 14th. Chardan Capital reissued a buy rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research report on Friday, August 9th.

View Our Latest Stock Analysis on GANX

Gain Therapeutics Trading Up 4.9 %

Shares of GANX stock opened at $1.72 on Tuesday. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $5.33. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $1.30 and its two-hundred day moving average is $2.05. The company has a market cap of $31.05 million, a PE ratio of -1.15 and a beta of 0.42.

Gain Therapeutics (NASDAQ:GANX – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.11). Equities analysts predict that Gain Therapeutics will post -1.05 EPS for the current year.

Insider Activity

In other Gain Therapeutics news, Chairman Khalid Islam acquired 50,000 shares of Gain Therapeutics stock in a transaction dated Friday, August 9th. The stock was bought at an average cost of $1.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the chairman now owns 50,000 shares of the company’s stock, valued at $50,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Warberg Asset Management LLC bought a new position in Gain Therapeutics in the second quarter worth $66,000. Renaissance Technologies LLC lifted its position in Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares during the period. Finally, Hohimer Wealth Management LLC bought a new position in Gain Therapeutics in the second quarter worth $422,000. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Company Profile

(Get Free Report)

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

Further Reading